



<b>National Imaging Associates, Inc.</b>	
<b>Clinical Guideline: NON SMALL CELL LUNG CANCER</b>	<b>Original Date: March 2011</b>
<b>Radiation Oncology</b>	<b>Last Revised Date: April 2019</b>
<b>Guideline Number: NIA_CG_122</b>	<b>Implementation Date: January 2020</b>

## INDICATIONS FOR RADIATION THERAPY

**Three-dimensional conformal radiation therapy (3D-CRT)** is considered medically necessary for the following clinical indications (NCCN, 2019):

- Post Operative Radiation Therapy (NCCN, 2019)
  - Positive Nodes (N 1-3) **or**
  - Positive or close margins

Dosage Guidelines (NCCN, 2019):

  - Extracapsular nodal extension or positive margins: 54-60 Gy up to 33 fractions
  - Gross Residual Tumor 60-70 Gy up to 39 fractions
  - Negative margins: 50-54 Gy up to 30 fractions
- Pre Operative Radiation Therapy (NCCN, 2019)
  - T3-4, N0-N1 **or**
  - Resectable Superior Sulcus Tumors **or**
  - N2 disease (Stage IIIA ,T 1-3, N2)

Dosage Guidelines (NCCN, 2019):

  - 45-54 Gy up to 30 fractions
- Inoperable – Definitive (NCCN, 2019)
  - Stage I disease (T1-2a, N0, M0)
  - Stage II and Stage III disease (T2b-T4, N0, M0 or T1-4, N1-3, M0)

**or**

  - Surgery Refused

Dosage Guidelines (NCCN, 2019):

  - 60-70 Gy up to 39 fractions
- Palliative Radiation Therapy is considered medically necessary for Stage IV (M1) disease to relieve pain, airway or endobronchial obstruction, and other symptoms (NCCN, 2019)

*Unless otherwise indicated standard radiation fractionation consists of 1.8 Gy to 2.0 Gy per day.*

**Stereotactic Body Radiation Therapy (SBRT)** is considered medically necessary for patients with inoperable Stage I or II disease or patients who refuse to have surgery (NCCN, 2019).

Dosage Guidelines:

- Delivered at 5 fractions or less

**Endobronchial Brachytherapy** is considered medically necessary for the following clinical indications (NCCN, 2019):

- Patients with primary tumors who are not otherwise candidates for surgical resection or external-beam radiation therapy due to co-morbidities or location of the tumor
- Palliative therapy for airway obstruction or severe hemoptysis in patients with primary, metastatic, or recurrent tumors.

#### **TREATMENT OPTIONS REQUIRING PHYSICIAN REVIEW**

##### **Intensity Modulated Radiation Therapy (IMRT)**

IMRT is not indicated as a standard treatment option and should not be used routinely for the delivery of radiation therapy for non small cell lung cancer. IMRT may be appropriate for limited circumstances in which radiation therapy is indicated and 3D conformal radiation therapy (3D-CRT) techniques cannot adequately deliver the radiation prescription without exceeding normal tissue radiation tolerance, the delivery is anticipated to contribute to potential late toxicity or tumor volume dose heterogeneity is such that unacceptable hot or cold spots are created. If IMRT is utilized, techniques to account for respiratory motion should be performed.

Clinical rationale and documentation for performing IMRT rather than 2D/3D-CRT treatment planning and delivery will need to:

- Demonstrate how 2D-3D-CRT isodose planning cannot produce a satisfactory treatment plan (as stated above) via the use of a patient specific dose volume histograms and isodose plans.
- Provide tissue constraints for both the target and affected critical structures.

##### **Proton Beam Radiation Therapy (PBT)**

Proton Beam is not indicated as a standard treatment option and should not be used routinely for the delivery of radiation therapy for non small cell lung cancer.

##### **Stereotactic Body Radiation Therapy**

Stereotactic Body Radiation Therapy (SBRT) is not considered a standard form of treatment for NSCLC except for inoperable Stage I and II disease. Other requests for SBRT will require a peer review to make a medical necessity determination. Documentation from the radiation oncologist must include the clinical rationale for performing SBRT rather than 3-D conformal treatment (ASTRO, 2013).

#### **THE FOLLOWING APPLIES TO CMS (MEDICARE) MEMBERS ONLY:**

*For Proton Beam Radiation refer to Local Coverage Determination (LCD), if applicable.*

---

---

#### **BACKGROUND:**

Lung cancer is the leading cause of cancer-related deaths of both men and women in the United States. The World Health Organization divides lung cancer into two types: non-small cell lung cancer (NSCLC) as discussed in this guideline and small cell lung cancer (SCLC). The most common lung cancer, NSCLC, includes various histologies: squamous carcinoma, adenocarcinoma, and large cell carcinoma. Surgery alone has been the standard treatment for patients with resectable NSCLC for many years. However, patients with completely resected disease have disappointing survival rates. In some cases, relapse occurs at distant sites which suggest that NSCLC may be a systemic disease when diagnosed.

Chemotherapy and radiation therapy are now treatment considerations in both the preoperative and postoperative settings.

Prognosis and treatment of NSCLC are based on the staging of the cancer which documents the extent of cancer growth and spread. The initial goal of staging is to determine if the tumor is surgically resectable. Some patients with resectable disease may be cured by surgery while others, due to contraindications to surgery, may be candidates for radiation therapy for curative intent or for local control.

This guideline outlines several methods suitable for the delivery of radiation therapy to treat lung cancer. These include the use of external beam radiation therapy such as; three-dimensional conformal radiation therapy (3D-CRT), endobronchial brachytherapy, postoperative radiation therapy (PORT) and stereotactic body radiation (SBRT). Endobronchial brachytherapy and SBRT are aggressive approaches justified, in part, for non-resectable tumors. While these advances in treatment offer a range of regimens, the goal of this guideline is to guide diagnosis and treatment to the most efficient, comparatively effective, diagnostic and treatment pathway. With the exception of medically inoperable tumors and extreme palliative circumstances, radiation treatment is performed, in most cases, in conjunction with surgical intervention.

**POLICY HISTORY:**

**Review Date: February 2019**

**Review Summary: Added and updated references**

## REFERENCES:

American Society for Radiation Oncology (ASTRO). Model Policy. Proton Beam Therapy. [https://www.astro.org/uploadedFiles/\\_MAIN\\_SITE/Daily\\_Practice/Reimbursement/Model\\_Policies/Content\\_Pieces/ASTROPBTModelPolicy.pdf](https://www.astro.org/uploadedFiles/_MAIN_SITE/Daily_Practice/Reimbursement/Model_Policies/Content_Pieces/ASTROPBTModelPolicy.pdf). Published May 20, 2014. Accessed May 18, 2016.

American Society of Therapeutic Radiation Oncology (ASTRO). Stereotactic Body Radiation Therapy (SBRT). [https://www.astro.org/uploadedFiles/Main\\_Site/Practice\\_Management/Reimbursement/2013HPcoding%20guidelines\\_SBRT\\_Final.pdf](https://www.astro.org/uploadedFiles/Main_Site/Practice_Management/Reimbursement/2013HPcoding%20guidelines_SBRT_Final.pdf). Updated April 17, 2013. Retrieved March 10, 2015.

Bentzen SM, Constine LS, Deasy JO, et al. Quantitative analyses of normal tissue effects in the clinic QUANTEC: An introduction to the scientific issues. Introductory paper. *Int J Radiat Oncol Biol Phys*. 2010; 76(3):S3-S9.

Bezjak A, Temin S, Franklin G, et al. Definitive and adjuvant radiotherapy in locally advanced non–small-cell lung cancer: American Society of Clinical Oncology clinical practice guideline endorsement of the American Society for Radiation Oncology evidence-based clinical practice guideline. *J Clin Oncol*. June 2015; 33(18):2100-2105. <http://ascopubs.org/doi/full/10.1200/JCO.2014.59.2360>. Accessed May 15, 2017.

Bezjak A, Rumble RB, Rodrigues G, et al. Intensity-modulated radiotherapy in the treatment of lung cancer. [Published online ahead of print June 20, 2012]. *Clin Oncol (R Coll Radiol)*. September 2012; 24(7):508-520. doi: 10.1016/j.clon.2012.05.007.

Chan C. Intensity-modulated radiotherapy for lung cancer: Current status and future developments. *J Thorac Oncol*. November 2014; 9(11):1598-1608.

Choosing Wisely®. Key Word: Lung Cancer. [http://www.choosingwisely.org/clinician-lists/#keyword=Lung\\_Cancer&parentSociety=American\\_Society\\_for\\_Radiation\\_Oncology](http://www.choosingwisely.org/clinician-lists/#keyword=Lung_Cancer&parentSociety=American_Society_for_Radiation_Oncology). Accessed May 15, 2017.

Gomez DR, Chang JY. Accelerated dose escalation with proton beam therapy for non-small cell lung cancer. *J Thorac Dis*. <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3968555/>. April 2014. Accessed May 18, 2016.

Jackson A, Marks LB, Bentzen SM, et al. The lessons of QUANTEC: Recommendations for reporting and gathering data on dose-volume dependencies of treatment outcome. *Int J Radiat Oncol Biol Phys*. 2010; 76(3):S155-S160.

Moeller B, Balagamwala EH, Chen A, et al. Palliative thoracic radiation therapy for non-small cell lung cancer: 2018 Update of an American Society for Radiation Oncology (ASTRO) Evidence-Based Guideline. [https://www.practicalradonc.org/article/S1879-8500\(18\)30069-9/abstract](https://www.practicalradonc.org/article/S1879-8500(18)30069-9/abstract). Accessed May 2, 2018.

National Comprehensive Cancer Network (NCCN). Non-Small Cell Lung Cancer.3.2019. [https://www.nccn.org/professionals/physician\\_gls/pdf/nscl.pdf](https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf). Accessed February 11, 2019.

Reviewed / Approved by  Patrick Browning, VP, Medical Director

**Disclaimer:** Magellan Healthcare service authorization policies do not constitute medical advice and are not intended to govern or otherwise influence the practice of medicine. These policies are not meant to supplant your normal procedures, evaluation, diagnosis, treatment and/or care plans for your patients. Your professional judgement must be exercised and followed in all respects with regard to the treatment and care of your patients. These policies apply to all Magellan Healthcare subsidiaries including, but not limited to, National Imaging Associates (“Magellan”). The policies constitute only the reimbursement and coverage guidelines of Magellan. Coverage for services varies for individual members in accordance with the terms and conditions of applicable Certificates of Coverage, Summary Plan Descriptions, or contracts with governing regulatory agencies. Magellan reserves the right to review and update the guidelines at its sole discretion. Notice of such changes, if necessary, shall be provided in accordance with the terms and conditions of provider agreements and any applicable laws or regulations.